文献速递炎症性肠病

预防艰难梭菌感染及其复发的临床实践策略

Preventing Clostridioides difficile Infection and Recurrence: Practical Strategies for Clinical Practice.
PubMed 文献 · Am J Gastroenterol · 2026-10-28

本文综述了预防初发和复发性艰难梭菌感染(CDI)的当代证据,强调通过抗菌药物管理、感染防控、诊断管理及微生物组保护等措施减少可干预危险因素。对已发生CDI者,延长抗生素疗程、口服万古霉素预防及微生物组恢复疗法(包括粪菌移植和FDA批准的微生物组疗法)可恢复定植抵抗、实现二级预防。

要点

  • 初发预防核心:抗菌药物管理、感染防控、诊断管理及保护肠道微生物组。
  • 复发预防可选延长抗生素疗程、口服万古霉素预防及微生物组恢复疗法。
  • 高龄、免疫抑制、移植受者及炎症性肠病患者为复发高危人群。

核心结论

  • 预防是减少CDI长期疾病负担的中心策略,重点在于保护肠道微生物组和恢复定植抵抗。
  • 当前证据支持从治疗CDI发作转向实施个体化预防策略,以中断复发循环并改善长期结局。

研究设计与样本

  • 本文为综述,汇总支持初发和复发性CDI预防的当代证据,侧重消化内科医生的实用方法。

主要发现

  • 复发性CDI由肠道微生物组持续紊乱和定植抵抗丧失驱动。
  • 社区相关CDI发病率和复发性CDI负担持续构成临床挑战。
  • 微生物组恢复疗法(含粪菌移植和FDA批准的微生物组疗法)通过恢复微生物多样性和定植抵抗改变了二级预防。

关键数值与推荐

  • 初发预防:抗菌药物管理、感染预防与控制、诊断管理以区分定植与感染、保护肠道微生物组。
  • 二级预防:延长抗生素疗程、后续全身抗生素暴露期间口服万古霉素预防、微生物组恢复疗法。
  • 高危人群需特别考虑:老年人、免疫抑制者、移植受者及炎症性肠病患者。

临床怎么用

  • 消化内科医生应推行抗菌药物管理和诊断管理,减少可干预的CDI危险因素。
  • 对CDI患者评估延长抗生素疗程、口服万古霉素预防及微生物组恢复疗法的适用性。
  • 对高龄、免疫抑制、移植受者及炎症性肠病患者加强复发预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clostridioides difficile infection (CDI) is a major cause of morbidity, mortality, and healthcare utilization worldwide. Although advances in antimicrobial stewardship and infection prevention have reduced healthcare-associated disease in some settings, the incidence of community-associated CDI and the persistent burden of recurrent CDI (rCDI) continue to pose substantial clinical challenges. Because recurrent disease is fundamentally driven by persistent disruption of the intestinal microbiome and loss of colonization resistance, prevention has emerged as the central strategy for reducing long-term disease burden. This review summarizes contemporary evidence supporting prevention of both incident and rCDI, emphasizing practical approaches for gastroenterologists. Primary prevention centers on minimizing modifiable risk factors through antimicrobial stewardship, infection prevention and control, diagnostic stewardship to distinguish colonization from infection, and strategies to preserve the intestinal microbiome. For patients with CDI, we review evidence supporting extended antibiotic regimens, oral vancomycin prophylaxis during subsequent systemic antibiotic exposure, and microbiome restoration therapies, including conventional fecal microbiota transplantation and US Food and Drug Administration-approved microbiota-based therapies, which have transformed secondary prevention by restoring microbial diversity and colonization resistance. Special consideration is given to populations at particularly high risk for recurrence, including older adults, immunocompromised individuals, transplant recipients, and patients with inflammatory bowel disease. Finally, we discuss emerging preventive strategies, including precision risk stratification, microbiome- and metabolome-based biomarkers, bile acid modulation, and approaches targeting asymptomatic colonization. Together, these advances signal a paradigm shift from treating CDI episodes to implementing personalized preventive strategies that interrupt the cycle of recurrent disease and improve long-term patient outcomes.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Axelrad, Allegretti. Preventing Clostridioides difficile Infection and Recurrence: Practical Strategies for Clinical Practice. Am J Gastroenterol. 2026. PMID: 42949032. doi:10.14309/ajg.0000000000004239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。